Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06221267

A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Status
Recruiting
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is a single-arm, prospective, multicenter, observational registry study. It plans to enroll 120 migraine patients who meet the inclusion criteria and are treated with rimegepant in selected hospital outpatient clinics in the Greater Bay Area. The main purpose of this study is to observe the effectiveness of rimegepant in treating migraines in a real-world clinical setting, including the impact of rimegepant on the quality of life, functioning, productivity status of migraine patients, and patients' satisfaction with the use of rimegepant in treating migraines.

Conditions

Interventions

TypeNameDescription
DRUGRimegepantNo intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.

Timeline

Start date
2024-01-26
Primary completion
2024-05-31
Completion
2024-06-30
First posted
2024-01-24
Last updated
2024-04-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06221267. Inclusion in this directory is not an endorsement.

A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area (NCT06221267) · Clinical Trials Directory